Scholarlink

Background <p>Worm-induced small bowel obstruction (SBO) is a common pediatric surgical problem in endemic regions, but the role of oral Gastrografin in this setting remains unclear.</p> Methods <p>We conducted a prospective cohort study (December 2022–December 2024) at a single center in Pakistan. Children aged 5–18 years with radiological and clinical evidence of uncomplicated Ascaris-related SBO were included. Exclusions were complicated obstruction, rectal bleeding, hypersensitivity to Gastrografin, or refusal to participate. Participants received either standard conservative management (nil per os, nasogastric decompression, intravenous fluids, antibiotics, enemas, antispasmodics) or the same regimen plus Gastrografin 2 mL/kg via nasogastric tube (diluted 1:1 with saline). The primary outcome was hospital length of stay (LOS). Secondary outcomes were time to oral intake, pain resolution, passage of flatus and stool, laparotomy, and in-hospital complications.</p> Results <p>One hundred and twenty children were enrolled (60 per group). Baseline characteristics were similar. Gastrografin was associated with a shorter LOS (35 ± 15 vs. 60 ± 15&#xa0;h; mean difference − 25.0, 95% CI − 30.4 to − 19.6; <i>p</i> &lt; 0.001). Recovery milestones occurred earlier, including oral intake (30.2 ± 6.0 vs. 60.5 ± 15.6&#xa0;h), pain resolution (14.2 ± 4.5 vs. 45.8 ± 12.4&#xa0;h), passage of flatus (20.9 ± 9.0 vs. 48.8 ± 12.1&#xa0;h), and stool (15.9 ± 8.0 vs. 48.8 ± 12.1&#xa0;h) (all <i>p</i> ≤ 0.002). Laparotomy was infrequent (3/60 vs. 5/60; <i>p</i> &gt; 0.05). No Gastrografin-related adverse events occurred under hydration protocols.</p> Conclusions <p>In this cohort, oral Gastrografin as an adjunct to conservative care was associated with faster recovery and shorter hospitalisation without new safety concerns. Multicenter randomized studies are needed to confirm effectiveness and guide standardised protocols.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Oral gastrografin protocol resolves worm-induced small bowel obstruction in children: a prospective cohort study

  • 期刊论文

  • 发表日期：

    2026年3月16日

查看全文
  • Muhammad Kabir,
  • Saddar Rahim,
  • Husna Irfan Thalib,
  • Hafsa Kabir,
  • Noaman Khan,
  • Sami Ullah

摘要

Background

Worm-induced small bowel obstruction (SBO) is a common pediatric surgical problem in endemic regions, but the role of oral Gastrografin in this setting remains unclear.

Methods

We conducted a prospective cohort study (December 2022–December 2024) at a single center in Pakistan. Children aged 5–18 years with radiological and clinical evidence of uncomplicated Ascaris-related SBO were included. Exclusions were complicated obstruction, rectal bleeding, hypersensitivity to Gastrografin, or refusal to participate. Participants received either standard conservative management (nil per os, nasogastric decompression, intravenous fluids, antibiotics, enemas, antispasmodics) or the same regimen plus Gastrografin 2 mL/kg via nasogastric tube (diluted 1:1 with saline). The primary outcome was hospital length of stay (LOS). Secondary outcomes were time to oral intake, pain resolution, passage of flatus and stool, laparotomy, and in-hospital complications.

Results

One hundred and twenty children were enrolled (60 per group). Baseline characteristics were similar. Gastrografin was associated with a shorter LOS (35 ± 15 vs. 60 ± 15 h; mean difference − 25.0, 95% CI − 30.4 to − 19.6; p < 0.001). Recovery milestones occurred earlier, including oral intake (30.2 ± 6.0 vs. 60.5 ± 15.6 h), pain resolution (14.2 ± 4.5 vs. 45.8 ± 12.4 h), passage of flatus (20.9 ± 9.0 vs. 48.8 ± 12.1 h), and stool (15.9 ± 8.0 vs. 48.8 ± 12.1 h) (all p ≤ 0.002). Laparotomy was infrequent (3/60 vs. 5/60; p > 0.05). No Gastrografin-related adverse events occurred under hydration protocols.

Conclusions

In this cohort, oral Gastrografin as an adjunct to conservative care was associated with faster recovery and shorter hospitalisation without new safety concerns. Multicenter randomized studies are needed to confirm effectiveness and guide standardised protocols.